Los Angeles Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-116,560
| Closed | -$1.76M | – | 1309 |
|
|
2022
Q3 | $1.76M | Buy |
116,560
+71,907
| +161% | +$836K | 0.01% | 530 |
|
|
2022
Q2 | $335K | Sell |
44,653
-140
| -0.3% | -$987 | ﹤0.01% | 1109 |
|
|
2022
Q1 | $408K | Buy |
+44,793
| New | +$345K | ﹤0.01% | 1114 |
|
|
2021
Q1 | – | Sell |
-15,885
| Closed | -$215K | – | 1678 |
|
|
2020
Q4 | $215K | Sell |
15,885
-125
| -0.8% | -$1.51K | ﹤0.01% | 1456 |
|
|
2020
Q3 | $188K | Hold |
16,010
| – | – | ﹤0.01% | 1399 |
|
|
2020
Q2 | $236K | Buy |
+16,010
| New | +$237K | ﹤0.01% | 1355 |
|
|
2019
Q3 | – | Sell |
-15,157
| Closed | -$448K | – | 1400 |
|
|
2019
Q2 | $448K | Hold |
15,157
| – | – | ﹤0.01% | 1076 |
|
|
2019
Q1 | $720K | Buy |
+15,157
| New | +$667K | ﹤0.01% | 974 |
|
|
2018
Q4 | – | Sell |
-8,360
| Closed | -$515K | – | 1416 |
|
|
2018
Q3 | $515K | Sell |
8,360
-7,070
| -46% | -$454K | ﹤0.01% | 1085 |
|
|
2018
Q2 | $1.04M | Buy |
15,430
+2,140
| +16% | +$120K | 0.01% | 882 |
|
|
2018
Q1 | $721K | Buy |
+13,290
| New | +$743K | ﹤0.01% | 922 |
|
|
2017
Q4 | – | Sell |
-5,670
| Closed | -$276K | – | 1417 |
|
|
2017
Q3 | $276K | Buy |
+5,670
| New | +$309K | ﹤0.01% | 1173 |
|
Los Angeles Capital Management's AERI Position: Q4 2022 in Review
Los Angeles Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 116,560 shares — an estimated $1.76M sold.
Los Angeles Capital Management first reported a position in AERI in Q3 2017 and held it in 12 quarters. The position peaked at $1.76M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Los Angeles Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Los Angeles Capital Management sold 116,560 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.76M.
- Los Angeles Capital Management first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 12 quarters.
- Los Angeles Capital Management's Aerie Pharmaceuticals position peaked at $1.76M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Los Angeles Capital Management's 13F filing for Q4 2022, filed 6 Feb 2023.